and regenreon, reports at the conference and ceo schleifer on. space you won't want to miss. >> thanks, meg. >>> and biotech stocks among top performers should you keep betting on them in the new year? carter is at the plaza to break it down. >> i like them keep betting on them in the new year look at the charts see if it makes sense when we do since inception, ibb we know when you have dynamic groundbreaking, life-changing product, you can have dynamic groundbreaking life-changing results. ibb doubled the performance of the general equity market since launch a lot of different companies but the point is as a theme as a bet as an aggregate a place you want to be long term. the issue, underperformance of the past three years having peaked some three years ago, i have that same long-term trajectory on the bottom, relative performance to the s&p what we know is, that this has come down to this line and bounced and bounced and bounced and bounced and we're right down there again. it's my thinking that having underperformed we're about to get outperfo